Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Public ClinicalTrials.gov record NCT01843374. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.
Study identification
- NCT ID
- NCT01843374
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 571 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 17, 2013 (Actual)
- Primary completion
- Jan 24, 2016 (Actual)
- Completion
- May 31, 2027 (Estimated)
- Last update posted
- Jul 27, 2026
2013 – 2027
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | San Francisco | California | 94143 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | New Haven | Connecticut | 06511 | — |
| Research Site | Newark | Delaware | 19718 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Peoria | Illinois | 61615 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Baltimore | Maryland | 21231 | — |
| Research Site | Minneapolis | Minnesota | 55445 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Canton | Ohio | 44710 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01843374, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01843374 live on ClinicalTrials.gov.